PATENT CLAIM ANALYSIS

Application Number: 15902628
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["514", "653000"]

Abstract:
The present invention relates to pharmaceutical compositions comprising a 2-amino-2-[2-( 4 -C 2-20 - alkyl-phenyl)ethyl]propane-1,3-diol compound or a pharmaceutically acceptable salt thereof, and to the use thereof for treating, preventing or delaying the progression of multiple sclerosis in a paediatric patient or a patient suffering from a specific condition.

Claim (Index 9):
A method of treating, preventing or delaying the progression of multiple sclerosis in a a pediatric patient or a patient suffering from a chronic or recurrent condition selected from dyspnea, diarrhea, nausea and asthma, comprising orally administering to said patient about 1.25 mg, 0.5 mg or less of a 2-amino-2-[2-(4-C 2-20  alkylphenyl)ethyl]propane-1,3-diol compound or a pharmaceutical acceptable salt thereof.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 88.0
- Lexical Diversity: 1.22917
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14009241', '12682343', '14631102', '15437365', '15545800']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7563751396275535
- 35 USC 102 Novelty (BERT): 0.5088607279713437
- Combined Prediction Score: 0.7316236984619326
- Mean Citation Score: 197.477922
- Max Citation Score: 202.84822
- Similarity Product: 112.916256186167

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test